Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
MaxLinear Inc. reported a 48% year-over-year revenue jump for Q4 2025, powered by its infrastructure business, even as it manages a near-term dip in broadband and intensifying competition in key markets.
Chip designer MaxLinear capped off a transformative 2025 with a strong fourth quarter, reporting 30% full-year revenue growth and positive cash flow ahead of schedule. CEO Kishore Seendripu pointed to surging demand in data center optical interconnects and wireless infrastructure as key catalysts, positioning the company for even faster growth in 2026.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
Hawxhurst LLP has filed a federal lawsuit against International Amusement Rides and Intamin Ltd., alleging the roller coaster manufacturers failed to pay $1.5 million in legal fees after the firm defended them in high-stakes intellectual property battles.
The Ermenegildo Zegna Group reported a 1.1% organic revenue increase to €1.91 billion for 2025, powered by robust DTC performance. While annual sales dipped slightly on a reported basis, a strong fourth-quarter acceleration signals the payoff of its strategic channel shift.
ExxonMobil's 2025 year-end results underscore a reshaped corporate strategy, delivering record shareholder returns and production milestones in Guyana and the Permian, while advancing carbon capture and enterprise digitalization.
Fortinet's latest platform upgrade aims to consolidate cloud security management, targeting operational efficiency and investor confidence as it battles rivals in a crowded market.
